4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates

Company Performance - 4D Molecular Therapeutics reported a quarterly loss of $0.98 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.88, and compared to a loss of $0.63 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $0.02 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 98.58%, while revenues were zero a year ago [2] - The stock has added about 1.1% since the beginning of the year, underperforming the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.93 on revenues of $1.06 million, and for the current fiscal year, it is -$3.45 on revenues of $4.17 million [7] - The estimate revisions trend for 4D Molecular Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Medical - Drugs industry, to which 4D Molecular Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]